Arctic Bioscience

ABS

NO0010859580

Pharmaceuticals

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-05-22 EDT			5-day change	1st Jan Change
9.9 ^NOK	+5.88%		+1.02%	-5.71%

03-01	Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-01	Transcript : Arctic Bioscience AS, Q4 2023 Earnings Call, Mar 01, 2024

Arctic Bioscience as Maintains Earnings Guidance for the Year 2022

October 31, 2022 at 03:00 am

Arctic Bioscience AS maintained earnings guidance for the year 2022. The Company maintains the earlier communicated financial outlook of a y/y revenue growth in 2022 of 60-70 %.

Latest news about Arctic Bioscience

Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2023	03-01	CI
Transcript : Arctic Bioscience AS, Q4 2023 Earnings Call, Mar 01, 2024	03-01
Arctic Bioscience Announces Treatment start for 519 patients in the HeROPA-Study	02-28	CI
Arctic Bioscience Completes Patient Enlistment for Psoriasis Drug Candidate’s Mid-stage Study	01-17	MT
Arctic Bioscience Announces Recruitment Completed in the Phase IIb HeROPA Clinical Trial	01-17	CI
Arctic Bioscience Announces More Than 75% Recruitment in the Phase IIb HeROPA Clinical Trial	12-01	CI
Arctic Bioscience AS Provides Revenue Guidance for the Year 2023	11-02	CI
Transcript : Arctic Bioscience AS, H1 2023 Earnings Call, Aug 29, 2023	23-08-29
Arctic Bioscience AS Provides Earnings Guidance for the Year 2023	23-08-29	CI
Arctic Bioscience AS Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Arctic Bioscience Establishes Credit Facility of NOK 30 Million	23-07-07	CI
Arctic Bioscience as Announces Operational Update - Heropa Clinical Trial Approved in All 5 Countries and Ongoing	23-05-08	CI
Arctic Bioscience AS Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Arctic Bioscience Secures Approval for Psoriasis Treatment Trial in Norway, Finland, Germany, Poland	23-03-07	MT
Arctic Bioscience - The HeROPA phase IIb clinical trial approved in Norway, Finland, Germany and Poland	23-03-07	CI
Arctic Bioscience Buys Norwegian Microalgae Producer Arctic Algae	23-02-13	MT
Arctic Bioscience AS (OB:ABS) acquired Arctic Algae As from Ronja Capital II AS for enterprise value NOK 16.3 million.	23-02-12	CI
Arctic Bioscience Recruits First Patient For UK Psoriasis Investigational Medication Trial	23-02-01	MT
Arctic Bioscience Announces First Patient Included in HRO350 Phase IIb Clinical Trial in the UK	23-01-31	CI
UK Regulators Approve Arctic Bioscience's Clinical Trial Application For Psoriasis Medication	23-01-12	MT
Arctic Bioscience Announces Clinical Trial Application for HRO350 Phase IIb Approves in UK	23-01-12	CI
Arctic Bioscience as Maintains Earnings Guidance for the Year 2022	22-10-31	CI
Norway's Arctic Bioscience Submits Application To Launch Mid-stage Trial Of Psoriasis Drug	22-10-10	MT
Arctic Bioscience Submits Clinical Trial Application for Hro350 Phase IIb	22-10-09	CI
Arctic Bioscience Nears Submission of Application to Start Study of Psoriasis Drug	22-10-03	MT

Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscienceâs purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Ratings for Arctic Bioscience

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

9.9 NOK

Average target price

10 NOK

Spread / Average Target

+1.01%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ARCTIC BIOSCIENCE	-5.71%	22.23M
ELI LILLY AND COMPANY	+37.74%	723B
NOVO NORDISK A/S	+32.22%	598B
JOHNSON & JOHNSON	-2.07%	364B
MERCK & CO., INC.	+20.25%	331B
ABBVIE INC.	+2.99%	288B
ASTRAZENECA PLC	+16.60%	244B
NOVARTIS AG	+9.77%	210B
ROCHE HOLDING AG	-5.15%	208B
AMGEN INC.	+7.43%	169B

Other Pharmaceuticals